VolitionRx
Builds blood-based diagnostics from nucleosome measurement and chromatin enrichment.
Something off on this page? Send us feedback.
Profile
Develops blood-based diagnostic technologies based on nucleosome measurement and chromatin enrichment, selling veterinary tests, research-use kits, and laboratory services while developing human-health assays. Revenue combines products and services with a partner-led licensing model that relies on clinical validation, regulatory clearance, reimbursement, analyzer integration, and distribution.
Develops blood-based diagnostic technologies that measure circulating nucleosomes or enrich tumor-associated chromatin for liquid-biopsy analysis. Its Nu.Q platform spans commercially available canine cancer screening, a CE-marked Nu.Q NETs assay, and research-use Nu.Q Discover kits and laboratory services. Nu.Q Cancer and Capture-PCR/Capture-Seq remain development programs.
Generates product and service revenue and pursues licenses, milestones, and royalties, while keeping research and development, key assay components, and intellectual property in-house. Research and production are centered in Belgium, but commercialization runs through diagnostics partners, reference laboratories, analyzer platforms, and regional distributors across several markets.
Clinical validation, jurisdiction-specific authorization, reimbursement, installed-platform integration, and partner execution determine the timing and reach of its diagnostic products.
Company facts
Key statistics
Year to date −91.8% · Average volume (30d) 15.1M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.57 | −$0.85 | −49.8% | $415.3K | $398.7K | −4.0% | −6.96% |
| May 14, 2026Q1 FY26 | −$0.70 | −$0.97 | −38.6% | $1.5M | $985.1K | −35.2% | −9.09% |
| Mar 31, 2026Q4 FY25 | −$0.70 | −$1.05 | −50.0% | $753.6K | $420.0K | −44.3% | −0.99% |
| Nov 13, 2025Q3 FY25 | −$0.04 | −$0.04 | 0.0% | $1.7M | $627.3K | −62.7% | −6.63% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $246.4K | $406.7K | $627.3K | $447.0K | $985.1K | $398.7K | |
| Gross profit | $246.4K | $406.7K | $627.3K | $447.0K | $730.7K | $398.7K | |
| Operating income | −$5.5M | −$6.3M | −$5.1M | −$4.7M | −$5.3M | −$4.2M | |
| Net income | −$5.4M | −$6.3M | −$5.4M | −$6.3M | −$6.7M | −$7.3M | |
| Diluted EPS | −$1.12 | −$1.22 | −$1.00 | −$1.05 | −$0.97 | −$0.85 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 74.2% | 100.0% | |
| Operating margin | -2,241.1% | -1,548.6% | -813.2% | -1,058.4% | -543.0% | -1,042.5% |
Fiscal years (4-quarter sums)FY24 $1.2M · FY25 $1.7M
Balance sheet, Jun 30, 2026Cash & short-term investments $2.8M · Total debt $12.0M · Total assets $8.3M · Shareholders' equity −$32.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 12.04M · Float 6.66M · 55.3% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Lagoda Investment Management, L.P. | 1.46M | 12.09% | 13F | Aug 14, 2026 |
| Luminus Management LLC | 156.9K | 1.30% | 13F | Aug 14, 2026 |
| Geode Capital Management, LLC | 55.5K | 0.46% | 13F | Aug 12, 2026 |
| Vanguard Capital Management LLC | 50.7K | 0.42% | 13F | Aug 13, 2026 |
| Wealthspire Advisors, LLC | 45.0K | 0.37% | 13F | Aug 11, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Abbott
Cancer screening and MRD monitoring scale through Exact Sciences.
- Guardant Health
Blood-based screening, profiling, and monitoring across cancer care.
- GRAIL
Multi-cancer blood screening targets the same early-detection pathway.
- Caris Life Sciences
Multi-cancer blood testing and molecular profiling compete for oncology use.
- Natera
ctDNA MRD testing contests cancer recurrence and treatment monitoring.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| VolitionRx | $0.4091 | −8.46% | $3.7M | — | — | 1.5 | −0.3% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| GRAIL | $80.00 | −0.01% | $3.43B | — | — | 20.8 | +25.7% |
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Median | 53.9 | 60.5 | 17.3 | +37.7% |